Changeflow GovPing Pharma & Drug Safety MicroRNA from Rhodiola for Fibroplasia Treatment
Routine Notice Added Final

MicroRNA from Rhodiola for Fibroplasia Treatment

Favicon for changeflow.com ChangeBridge: Patent Apps - Biotech (C12N)
Published
Detected
Email

Summary

USPTO published patent application US20260091052A1 filed by Beijing Baishihekang Pharmaceutical Technology covering microRNA derived from Rhodiola root for prevention and treatment of fibroplasia medical signs and syndromes. The application (No. 19319016) was filed September 4, 2025 and published April 2, 2026, listing five inventors including Chengyu Jiang and Jianchao Du. CPC classifications indicate pharmaceutical compositions and nucleic acid technologies.

What changed

The USPTO published a patent application (US20260091052A1) by Beijing Baishihekang Pharmaceutical Technology for a microRNA composition derived from Rhodiola root intended for preventing or treating fibroplasia. The application covers A61K 31/7105 compositions and C12N 15/113 nucleic acid technologies. The fibroplasia indication suggests applications for conditions involving excessive tissue scarring or fibrosis.

This patent publication is informational and does not impose compliance obligations on other entities. Pharmaceutical companies developing RNA-based therapeutics or fibrotic disease treatments should review the claims to assess potential patent overlap with their own research programs. No response or action is required by third parties; the application represents a defensive intellectual property filing by the assignee.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

MICRORNA AND USES THEREOF IN PREVENTION AND/OR TREATMENT OF FIBROPLASIA MEDICAL SIGN AND/OR SYNDROME

Application US20260091052A1 Kind: A1 Apr 02, 2026

Assignee

BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD

Inventors

Chengyu JIANG, Jianchao DU, Zhu LIANG, Jiantao XU, Yan ZHAO

Abstract

Provided are microRNA from a Rhodiola root and uses thereof in the prevention and/or the treatment of a fibroplasia medical sign and/or syndrome.

CPC Classifications

A61K 31/7105 C12N 15/102 C12N 15/113 C12N 15/63 C12N 2310/11 C12N 2310/14

Filing Date

2025-09-04

Application No.

19319016

View original document →

Get daily alerts for ChangeBridge: Patent Apps - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
September 4th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260091052A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Pharmaceutical Research Biotechnology Development
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Healthcare Intellectual Property

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.